A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers

Trial Profile

A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Tildrakizumab (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions
  • Sponsors Schering-Plough
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 14 Oct 2009 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 14 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top